![ECOG-ACRIN logo[19516]275×75](https://blog.ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
August 31, 2026
Insights on a new breast cancer treatment study, concerns about low uptake of genomic testing, and a preview of the Fall Group Meeting
August 31, 2026
Guidance for a zero embargo mandate from the National Institutes of Health that aims to accelerate free public access to research results
August 31, 2026
A Standing Main Member of ECOG-ACRIN since 2012
August 31, 2026
Timely information about research presented at medical meetings, recognition of research leaders, and more
August 25, 2026
This trial is evaluating a new immunotherapy approach for patients with high-risk multiple myeloma that has returned after initial treatment
July 31, 2026
This trial is testing an immune-based treatment combination (teclistamab and pomalidomide) for patients with multiple myeloma that has come back early
June 29, 2026
This study is using PET imaging to guide treatment for prostate cancer recurrence
June 29, 2026
Timely information about research presented at medical meetings, recognition of research leaders, and more
May 28, 2026
Dr. Anagnostou is honored as a world-renowned lung cancer translational research investigator
May 28, 2026
The group is recognizing Dr. Berlin for his sustained commitment to mentoring early- and mid-career investigators in cancer medicine
May 28, 2026
ACHIEVE (EA5221) is the first lung cancer clinical trial for older patients with metastatic NSCLC, comparing immunotherapy (pembrolizumab) with and without chemotherapy
May 28, 2026
Timely information about research presented at medical meetings, recognition of research leaders, and more